MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

The interactive version of the crossword that appears in Thursday’s Farming supplement. No cheating.

Scientists at the Broad Institute of MIT and Harvard have identified 4,208 previously unannotated open reading frames (ORFs) across 679 human-associated viral genomes using a high-throughput method ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The flu virus is lingering in Arizona and the season has been vicious. Pediatric flu deaths reached the highest level in ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Ten children died during the 2024-25 season, up from zero just five years ago. Experts say the spike comes as vaccination ...

Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.

Newer formulations are even more effective at preventing illnesses that commonly afflict seniors — perhaps even dementia.